Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured US Medicare reimbursement eligibility for eligible procedures ...

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...

Anteris Technologies Looks Bullish If DurAVR's PARADIGM Delivers

Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in ...
Seeking Alpha

FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

The PARADIGM Trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR ® THV compared to commercially available transcatheter aortic valve ...
Morningstar

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
HotCopper on MSN

Paradigm Biopharma advances phase 3 OA trial on tail of positive DSMB safety review

Late-stage drug developer Paradigm Biopharmaceuticals (ASX:PAR) has announced its pivotal Phase 3 PARA_OA_012 clinical trial ...